+1.224.938.9523

HUMAN AMYLOID IMAGING CONFERENCE

The 2021 edition of the conference has been cancelled. We look forward to seeing you in 2022!

2020 PROGRAM

The event was held at the Kovens Conference Center at the Florida International University. 


HAI’s mobile app provides all the information on the program (with ability to save sessions to your conference schedule), poster presentations, FAQs, logistics, past years’ keynote videocasts, etc.   

Scan the QR code with your mobile phone or access the download through this link: https://my.yapp.us/HAICONF

 

Wednesday, January 15, 2020
7:30 AMCheck-in and Continental Breakfast
8:15 AMIntroductions/Welcome NotesKeith Johnson, MD, Massachusetts General Hospital
8:30 AMDIDACTIC SESSION A: PET Technical/MethodsCHAIR: Chester Mathis, PhD, University of Pittsburgh
8:30 AMMulti-site and longitudinal studies considerationsRobert Koeppe, PhD, University of Michigan
8:55 AMCentiloidsChristopher Rowe, MD, Austin Health
9:20 AMIn silico and computational chemistry methods in the development of PET radiotracers for imaging alpha synucleinRobert Mach, PhD, University of Pennsylvania
9:45 AMPOSTER SESSION 1A and Coffee Break
10:30 AMDIDACTIC SESSION B: NeuropathologyCHAIR: William Klunk, MD, University of Pittsburgh
10:30 AMBasic neuropathology of Abeta, tau and a-synJulie Schneider, MD, Rush University
11:00 AMTechnical considerations for IHC, HC, biochemistryMilos Ikonomovic, MD, University of Pittsburgh
11:30 AMTechnical considerations for homogenate bindingLaetitia Lemoine, PhD, Karolinska Institute
12:00 PMMaturity states of plaques and tanglesMelissa Murray, PhD, Mayo Clinic
12:30 PMLunch
1:45 PMSESSION 1: TECHNICAL ICHAIRS:
Brad Christian, PhD, University of Wisconsin-Madison
Ansel Hillmer, PhD, Yale University
1:45 PMEvaluation of 18F-JNJ-067 as a tau tracerSuzanne Baker, PhD, Lawrence Berkeley National Laboratory
2:00 PMA direct comparison of tau imaging agents [F-18]AV-1451 AND [F-18]MK-6240 in human subjectsBrian Lopresti, MS, University of Pittsburgh
2:15 PMA multi-center comparison of [18F]flortaucipir, [18F]RO948 and [18F]MK6240 tau-PET tracers to detect optimal target ROIs for differential diagnosisRik Ossenkoppele, PhD, VU University Medical Center
2:30 PMCapturing extra-cerebral MK-6240 signal with surface projectionsJustin Sanchez, BA, Massachusetts General Hospital
2:45 PMDiscussion Session 1
3:15 PMKeynote Lecture
Pathology progression modelling in Alzheimer’s disease
(This lecture will be recorded)
Alan Evans, PhD, McGill University
3:45 PMKeynote Discussion
4:00 PMPOSTER SESSION 1B (repeat of 1A) and Coffee Break
4:45 PMSESSION 2: TECHNICAL IICHAIRS:
Julie Price, PhD, Harvard Medical School
Suzanne Baker, PhD, Lawrence Berkeley National Laboratory
4:45 PMAmyloid Load predicts elevated tau deposition in Down syndromeMatt Zammit, MS, University of Wisconsin
5:00 PMTauIQ demonstrates increased power for cross-sectional and longitudinal analysis of Tau tracers as evidenced by [18F]Flortaucipir and [18F]GTP1Roger Gunn, PhD, Invicro
5:15 PMSpatiotemporal imaging phenotypes of tau pathology in Alzheimer’s diseaseJacob Vogel, PhD (cand.), McGill University
5:30 PMPredicting structural, metabolic and pathologic disease progression in autosomal dominant Alzheimer’s disease with machine learningPatrick Luckett, PhD, Washington University in St. Louis
5:45 PMCorrection of partial volume effects for tau PET imaging using the kernel methodKuang Gong, PhD, MGH/Harvard Medical School
6:00 PMDiscussion Session 2
6:30 PMWelcome Reception
8:30 PMEnd of Day 1
Thursday, January 16, 2020
7:30 AMCheck-in and Continental Breakfast
8:30 AMSESSION 3: NEUROPATHOLOGY ICHAIRS
Laetitia Lemoine, PhD, Karolinska Institute
Teresa Gomez-Isla, MD, Massachusetts General Hospital
8:30 AMFlortaucipir PET often shows uptake greater in regions outside of the medial temporal lobe than in entorhinal cortex in low Braak tangle stage participantsVal Lowe, MD, Mayo Clinic
8:45 AMBrain volume and [18F]flortaucipir PET analysis of progressive supranuclear palsy clinical variantsJennifer Whitwell, PhD, Mayo Clinic
9:00 AMComparison of autoradiographic binding profiles of Flortaucipir, MK-6240 and PI-2620 in human postmortem tissue samples across the spectrum of neurodegenerative diseasesCinthya Aguero, MD, Massachusetts General Hospital
9:15 AMBiochemical correlates of tau and amyloid PET imaging in four autopsy brainsMilos Ikonomovic, MD, University of Pittsburgh
9:30 AMDiscussion Session 3
10:00 AMKeynote Lecture
Amyloid and tau: one of multiple pathways to tissue injury, degeneration, and Alzheimer’s dementia
(This lecture will be recorded)
Julie Schneider, MD, MS, Rush University
10:30 AMKeynote Discussion
10:45 AMPOSTER SESSION 2A and Coffee Break
11:30 AMSESSION 4: NEUROPATHOLOGY IICHAIRS
Melissa Murray, PhD, Mayo Clinic
Julie Schneider, MD, MS, Rush University
11:30 AMDerivation and potential utility of an Abeta-PET based pathology accumulation index for estimation of brain Abeta loadRuben Smith, MD, PhD, Lund University
11:45 AMIn vitro study of the evidence of tauopathy in Parkinson’s disease (PD) brains using a tau PET tracer, [3H]MK-6240, by autoradiographyZhizhen Zeng, MD, PhD, Merck & Co. Inc.
12:00 PMIn vitro characterization of second-generation tau pet tracers in human autopsy brain tissueMona-Lisa Malarte, PhD (cand.), Karolinska Institute
12:15 PMNeurofibrillary tangle maturity: a comprehensive reviewChristina Moloney, PhD, Mayo Clinic
12:30 PMDiscussion Session 4
1:00-2:30Lunch
2:30 PMSESSION 5: CLINICAL ICHAIRS:
Keith Johnson, MD, Massachusetts General Hospital
Pedro Rosa-Neto MD, PhD, McGill University
2:30 PMHistory of head injury is associated with greater tau deposition on [18F]Flortaucipir PET in MCI and AD PatientsShannon Risacher, PhD, Indiana University School of Medicine
2:45 PMIn vivo measurement of widespread synaptic loss in early Alzheimer’s disease with SV2A PETAdam Mecca, MD, PhD, Yale University
3:00 PMAmyloid PET is more than just positive or negative: Aβ-amyloid level impacts risk of clinical progression in non-demented individualsChristopher Rowe, MD, Austin Health
3:15 PM18F-PI2620 tau-PET in Progressive Supranuclear Palsy – a multi-center evaluationMatthias Brendel, MD, University Hospital of Munich
3:30 PMDiscussion Session 5
4:00 PMPOSTER SESSION 2B (repeat of 2A) and Coffee Break
4:45 PMSESSION 6: CLINICAL IICHAIRS
William Jagust, MD, University of California, Berkeley
David Wolk, MD, University of Pennsylvania
4:45 PMTau-PET associations with amyloid positivity and cognitive impairmentSusan Landau, PhD, University of California, Berkeley
5:00 PMLocus coeruleus integrity tracks with initial Alzheimer's disease-related pathology and cognitive declineHeidi Jacobs, PhD, Massachusetts General Hospital
5:15 PMArea 35 is the earliest subregion in the medial temporal lobe affected by tau pathologyDavid Berron, PhD, Lund University
5:30 PMDiscussion Session 6
6:00 PMNetworking Reception
8:00 PMEnd of Day 2
Friday, January 17, 2020
7:30 AMCheck-in and Continental Breakfast
8:30 AMSESSION 7A: TAU ICHAIRS
Tobey Betthauser, PhD, University of Wisconsin
Sylvia Villeneuve, PhD, McGill University
8:30 AMThe implications of different approaches to define AT(N) in Alzheimer's diseaseAntoine Leuzy, PhD, Lund University
8:45 AMTowards a CenTauR cortical maskVincent Dore, PhD, CSIRO
9:00 AMTau positivity: comparing flortaucipir meta-ROI vs. maximum of regional Z-scoresChristopher Schwarz, MD, Mayo Clinic
9:15 AMPOSTER SESSION 3A and Coffee Break
10:00 AMSESSION 7B: TAU IICHAIRS
Clifford Jack, MD, Mayo Clinic
Reisa Sperling, MD, Brigham and Women's Hospital
Victor Villemagne, MD, Austin Health
10:00 AMCritical threshold of elevated amyloid associated with rapid tau accumulation: a ca-tau-strophe in the makingKeith Johnson, MD, Massachusetts General Hospital
10:15 AMDefining a tau positive flortaucipir PET signal relative to AD neuropathologyMichael Pontecorvo, PhD, Avid Pharmaceuticals
10:30 AMLongitudinal tau PET changes in cognitively unimpaired persons with different β-amyloid levelsDavid Knopman, MD, Mayo Clinic
10:45 AMThe meaning of tau positivity with respect to clinical progressionMichael Devous, PhD, Avid Pharmaceuticals
11:00 AMDiscussion Session 7 (TAU I and TAU II)
12:00 PMKeynote Lecture
(This lecture will be recorded)
Li-Huei Tsai, PhD, Massachusetts Institute of Technology
12:30 PMKeynote Discussion
12:45 PMLunch
2:00 PMSESSION 8: CLINICAL IIICHAIRS
Elizabeth Mormino, PhD, Stanford University
Susan Landau, PhD, University of California, Berkeley
2:00 PMGlucose metabolism reflects local atrophy and tau pathology at symptomatic stages of Alzheimer's diseaseAmelia Strom, BS, University of California San Francisco
2:15 PMPlasma FLT1 predicts amyloid-β related cognitive decline in cognitively normal older adultsHyun-Sik Yang, MD, Brigham and Women's Hospital
2:30 PMReducing sample sizes to detect longitudinal amyloid accumulationIsadora Lopes Alves, PhD, VUmc
2:45 PMDiscussion Session 8
3:15 PMPOSTER SESSION 3B (repeat of 3A) and Coffee Break
4:00 PMAwards Ceremony
4:15 PMSESSION 9: PLASMACHAIRS
Oskar Hansson, PhD, Lund University
Gil Rabinovici, MD, UCSF
4:15 PMPlasma P-tau181 as a marker of tau pathology in Alzheimer’s disease: relationship to Tau PET, differential diagnosis, neuropathology and longitudinal progressionOskar Hansson, PhD, Lund University
4:30 PMPlasma levels of an N-terminal tau fragment are highly associated with future cognitive decline and neurodegeneration in clinically normal elderly: Findings from the Harvard Aging Brain StudyJasmeer Chhatwal, MD, MGH/Harvard University
4:45 PMPlasma biomarkers associate with amyloid and tau PET binding in cognitively unimpaired older adults with a parental history of ADPierre-Francois Meyer, PhD, McGill University
5:00 PMHigh-performance plasma phospho-tau181 biomarker for Alzheimer’s diseaseTharick Pascoal, PhD, McGill University
5:15 PMDiscussion Session 9
5:45 PMClosing NotesKeith Johnson, MD, Massachusetts General Hospital
6:00 PMEND OF MEETING

 

 

The 18th Mild Cognitive Impairment Symposium and Special Topic Workshop (CME/CE accredited) followed immediately on January 18-19, 2020 at the same venue. 

MCI website

2020 KEYNOTE LECTURES


ALAN EVANS, PhD

Dr. Alan Evans is a James McGill Professor of Neurology and Neurosurgery, Psychiatry and Biomedical Engineering at McGill University since 2009, and a researcher in the McConnell Brain Imaging Centre (BIC) of the Montreal Neurological Institute.

He is co-director of the Ludmer Centre for Neuroinformatics and Mental Health and is Principal Investigator of CBRAIN, a pan-Canadian project to integrate Canadian brain research with the Compute Canada high-performance computing grid. He is the sole Canadian participant in the $1.1 billion European Human Brain Project, and is a co-principal investigator of the Big Brain project. He is Scientific Director of McGill’s $84 million CFREF project, “Healthy Brains for Healthy Lives.”

Dr. Evans heads the Data Coordinating Center for a large NIH multi-centre MRI study of normal pediatric development. This provides a web-accessible reference database of neuroanatomical and behavioral maturation.  Dr. Evans was principal investigator in the Montreal Consortium for Brain Imaging Research (MCBIR), which was founded in 2000 with a $35 million award from the Canada Foundation for Innovation.  He was a co-founder of the International Consortium for Brain Mapping (ICBM), a multinational effort funded by the U.S. Human Brain Project to create a computational atlas of the adult human brain. He was one of the founders of the Organization for Human Brain Mapping (OHBM), serving in numerous positions on the OHBM Council since 1995.

Dr. Evans’ research interests include cognitive neuroimaging, neuroanatomical variability, and image-processing methodologies for PET and MRI. He pioneered the technique of multi-modal 3D brain imaging with PET and MRI, which provides detailed 3D images of brain anatomy.

As BIC Coordinator from 1992 to 2000, Dr. Evans fostered the development of brain “activation” studies in which specific brain regions show subtle changes in blood flow in response to cognitive and sensorimotor stimuli. This so-called brain-mapping technique is widely used to map human brain functions. Dr. Evans extended these techniques to large-scale studies of brain anatomy.  This work has spun off a new company, Biospective Inc., which performs fully automated analysis of neuroimaging databases collected as part of pharmaceutical clinical trials.

Dr. Evans has published over 550 peer-reviewed papers, and is a member of numerous international advisory boards, review panels and research collaborations. He was acknowledged as a Thompson-Reuters Highly Cited Scientist for 2014 and 2015 (top 1% in Neuroscience and Behaviour).

JULIE SCHNEIDER, MD, MS

Dr. Julie A. Schneider is the The Deborah R. And Edgar D. Jannotta Presidential Professor of Pathology (Neuropathology) and Neurological Sciences, and Associate Director at the Rush Alzheimer’s Disease Center, at Rush University Medical Center.  She completed her Neurology residency at the University of Chicago and Neuropathology fellowship at Emory University in Atlanta and is board certified in both specialties.

Dr. Schneider is also certified in Geriatric Neurology, and has a Master’s Degree in Clinical Research with a focus in Epidemiology.  She is the Neuropathology Core Leader of the Rush Alzheimer’s Disease Center and the senior neuropathologist for multiple studies including the Religious Orders Study, Rush Memory and Aging Project, and Rush Minority Aging Research Study, Rush Latino Core, and NCRAD (National Cell Repository for Alzheimer’s disease).  

Dr. Schneider has provided peer review for over 25 journals; has been invited to multiple journal editorial boards; and has provided numerous grant peer reviews for the National Institutes of Health, Alzheimer’s Association, and other agencies. She has served on numerous scientific and external national and international advisory boards for academia and industry; and has presented findings from her research both nationally and internationally.  

Dr. Schneider has extensive experience with clinical-pathologic epidemiologic studies of aging and dementia and has over 300 peer-reviewed publications and 4 book chapters.  She also has extensive experience collaborating with researchers, participating in multicenter grants and initiatives, and partnerships with industry to advance science.  

The foundation of Dr. Schneider’s research is the exploration of pathologic factors in the clinical expression of cognitive decline in aging, with a focus on vascular, TDP-43, hippocampal sclerosis and mixed pathologies in Alzheimer’s and related dementias.  

Dr. Schneider has over 300 peer-reviewed publications and an H-factor of 104.  Her current research leverages neuropathology to advance understanding of risk, methods for diagnosis, and biomarker development for vascular, TDP, and mixed pathologies.    

LI-HUEI TSAI, PhD

Dr. Li-Huei Tsai is a leader in understanding the molecular pathophysiology of neurological disorders affecting cognition. Her work has brought new mechanisms for learning, memory and neurodegeneration to light and suggests new paths for combating age-related memory loss.

Landmark discoveries include pinpointing major genetic risk for Alzheimer’s disease to immune genes, identifying chromatin-modifiers and kinases that regulate brain flexibility and can be targeted to improve cognition in Alzheimer’s disease, and discovering that genomic integrity is critical for neuronal protection during both aging and neurodegenerative disease.

In 2019, Dr. Tsai won the Hans Wigzell Prize in Medicine for 2018 for her innovative research in trying to understand the etiology and possible treatment of Alzheimer’s disease.  She is a recipient of the Young Investigator Award, Metropolitan Life Foundation, Outstanding Contributor Award of the Alzheimer Research Forum, the NIH Cantoni Lecture Award and the Glenn Award For Research in Biological Mechanisms of Aging.

Dr. Tsai is Director of the The Picower Institute for Learning and Memory, Picower Profess or Neuroscience and Senior Associate Member, Broad Institute.

She is a Fellow of the American Association for the Advancement of Science and a member of the Institute of Medicine of the National Academy of Sciences, the Neurodegeneration Consortium and Taiwan’s Academia Sinica.

Dr. Tsai has authored and co-authored over 130 peer-reviewed articles published in Nature, Cell, Neuron, Molecular Psychiatry, The Journal of Neuroscience, Nature Neuroscience, and the Proceedings of the National Academy of Sciences.  Her research has been featured in National Geographic and the Boston Globe.